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Abstract
Cell- and sex-specific differences in DNA methylation are major sources of epigenetic varia-
tion in whole blood. Heterogeneity attributable to cell type has motivated the identification of
cell-specific methylation at the CpG level, however statistical methods for this purpose have
been limited to pairwise comparisons between cell types or between the cell type of interest
and whole blood. We developed a Bayesian model selection algorithm for the identification
of cell-specific methylation profiles that incorporates knowledge of shared cell lineage and
allows for the identification of differential methylation profiles in one or more cell types simul-
taneously. Under the proposed methodology, sex-specific differences in methylation by cell
type are also assessed. Using publicly available, cell-sorted methylation data, we show that
51.3% of female CpG markers and 61.4% of male CpG markers identified were associated
with differential methylation in more than one cell type. The impact of cell lineage on differen-
tial methylation was also highlighted. An evaluation of sex-specific differences revealed dif-
ferences in CD56+NK methylation, within both single and multi- cell dependent methylation
patterns. Our findings demonstrate the need to account for cell lineage in studies of differen-
tial methylation and associated sex effects.
Introduction
DNA methylation is a widely studied epigenetic modification that plays an essential role in the
regulation of gene expression [1], cell differentiation [2] and the maintenance of chromatin
structure [3]. Advances in high-throughput technologies [4–6] have made possible the collec-
tion of DNA methylation at the genome scale, allowing its relationship with biological pro-
cesses to be interrogated. Studies of DNA methylation levels in humans, at both the global and
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individual CpG levels, have revealed associations between aberrant methylation profiles and
disease susceptibility [7], including carcinogenesis [8]. These studies have largely been con-
ducted using samples of whole blood, in light of its convenience as a source of DNA and viabil-
ity as a surrogate for target tissue. Its use, however, presents challenges for analysis and
interpretation [9].
The role of DNA methylation in haematopoiesis has motivated the search for cell-specific
methylation profiles at the individual CpG level and their association with lineage-specific
gene expression [10–12]. To date, the discovery of cell-specific CpG markers has been based
on the comparison of methylation levels between select purified cell subtypes [12] or against
methylation levels observed in whole blood [13]. In [13], DNA methylation levels for seven
purified cell subpopulations were compared and significant differences were identified
between Lymphocyte and Myeloid cell populations. The definition of cell-specific methylation
in this study and others was restricted the identification of differential methylation in a single
cell type. The impact of accounting for more complex methylation profiles based on shared
hematopoietic lineage remains unexplored.
Evidence of sex effects in DNA methylation is mixed and studies to date have focused pri-
marily on whole blood. Previous studies of global and autosomal CpG methylation have
reported a tendency for higher methylation in males [14] and sex-specific differences at vary-
ing numbers of CpG probes, across different chromosomes [15, 16]. A meta-analysis of pub-
lished findings [17] identified 184 sex-specific, autosomal CpG probes, although average
methylation differences were small and included studies did not account for cellular heteroge-
neity. Evidence for sex-specific methylation patterns for purified cell subtypes remains rela-
tively unexplored. A recent study [18] examined sex-specific methylation levels for four
purified immune cell subtypes (B cells, Monocytes, CD4+Foxp3-,CD8+T), and their role in
immune-mediated diseases. Cell-specific methylation patterns in females versus males were
compared and sex-specific differences were identified for each cell type. Similar to previous
studies of cell-specific methylation, the identification of these differences was restricted to a
single cell type, therefore precluding the exploration of sex-specific differences as a function of
cell lineage.
In light of current limitations, this paper proposes new methodology for the identification
of cell-specific methylation profiles at the individual CpG level and associated sex effects. Our
methodology incorporates knowledge about cell lineage to accommodate the identification of
differential methylation in one or multiple cell types, therefore expanding upon the range of
methylation patterns currently studied. The main component of the methodology is a model
choice algorithm, formulated within a Bayesian framework, which allows evidence for multiple
cell-specific methylation patterns to be assessed simultaneously. Using cell-sorted methylation
data from female and male samples, panels of cell-specific CpG markers are identified for each
sex and common marker panels are derived. Subsequent analysis of identified CpG markers
demonstrate the need to account for lineage in the discovery of cell-specific methylation
patterns.
Materials and methods
Ethics statement
Female training data were collected as part of a study of epigenetics and multiple sclerosis at
the Flory Institute in Melbourne, Australia. All patients involved provided informed consent
and the study was granted ethics approval by the Eastern Health and Melbourne Health
Human Research Ethics Committee. Remaining data used in this study were available from
published studies and accessed from public data repositories.
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Data
Publicly available Illumina 450K methylation data were obtained from six healthy males sub-
jects [13] (GEO Accession number: GSE35069). The data contained methylation β-values on
seven isolated cell populations: CD19B+ cells, CD14+ Monocytes, CD4+T cells, CD8+T cells,
CD56+ Natural Killers (NK), CD16+ Neutrophils (Neu) and Eosinophils (Eos). Samples of the
same cell types excluding Eosinophils were also obtained for five healthy female subjects, as
part of a larger study (GEO Accession number: GSE88824). The methodology described in
this paper was therefore applied to the six cell types common to both datasets. For both sexes,
445,603 CpG probes were available for analysis.
Consistent with previous findings [13], differences in DNA methylation levels across CpG
sites were primarily driven by cell type differences, as opposed to being an artefact of between-
subject variation (Fig 1). Cell lineage for each sex was subsequently inferred using hierarchical
agglomerative clustering, applied to methylation β−values for each cell type and CpG probe,
averaged over samples. Complete-linkage based on euclidean distance was assumed for the
successive merging of cell types, however the choice of clustering metric did not impact the
resulting hierarchy.
Additional cell sorted 450K methylation data on female and male subjects [18], aged 32-50
years, were obtained from public databases, for validation of model results. Female data con-
sisted of cell-sorted samples on six healthy subjects downloaded from ArrayExpress (Accession
number: E-ERAD-179) for CD19B+B cells, CD14+ Monocytes, CD4+T and CD8+ T cells.
Methylation data on six healthy male subjects from the same study were downloaded from
Gene Expression Ominibus (GEO Accession number: GSE71245). Following filtering and
normalisation, 436,067 and 445,307 CpG sites were available for validation for females and
males respectively, based on their correspondence with available sites in the training data.
Model formulation
The methodology presented in this paper was motivated by the identification of cell-specific
methylation at the individual CpG level. A cell-specific CpG was defined as any CpG probe
where the expected methylation level was different for one (single cell-specific) or more
(multi- cell-specific) cell types, relative to others observed. The true cell-specific methylation
pattern at each CpG probe was assumed unknown and treated as a model selection problem,
with key details outlined in this Section.
Fig 1. Left to right: Principal components plot over samples (Circle = Female, Triangle = Male); Dendrogram of cell-sorted
DNA methylation samples over 445,603 CpG probes for female and male samples; Comparison of inferred cell type lineage
by clustering metric (Complete linkage, Single linkage, UPGMA, MPGMA). The response variable was equal to the mean
methylation β−value by each cell type, at each CpG probe. UPGMA = Unweighted Pair Group Method with Arithmetic Mean,
WPGMA = Weighted Pair Group Method with Arithmetic Mean.
https://doi.org/10.1371/journal.pone.0182455.g001
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Using the results of hierarchical clustering (Fig 1), candidate models sought to characterise
methylation levels with respect to the cell type(s) associated with each dendrogram split or
node. This proposed approach to model specification was motivated by interest in identifying
differentially methylated CpGs associated with each stage of whole blood lineage. Shared line-
age was defined by the cell types present in a single split or node. In the corresponding candi-
date model, cell types with shared lineage were represented by unique, cell-specific means.
Non-member cell types were assumed to share the same level of methylation to define a refer-
ence level, as associated levels of methylation were not of direct interest. This approach
resulted in the specification of twelve candidate models, including the null and saturated cases
(Table 1).
Each candidate model was translated into a linear model, where each cell type grouping was
represented by a different mean parameter. For sex s, observed methylation β−values for each
cell type at CpG k were represented by the vector, yiks = (yiks1, . . ., yiksJ), for samples i = 1, . . ., ns.
The partition defined under each candidate model was encoded into the design matrix, Xm, of
size J × P(m), where P(m) was equal to the number of partitions for candidate model m. Mean
methylation levels for each partition were represented by the vector μðmÞks of length P
(m). The
likelihood for a single CpG probe k = 1, . . ., K under candidate model m was given by,
pðyksjμks; s2ks;Model mÞ ¼
Yns
i¼1
N JðXmμ
ðmÞ
ks ; s
2ðmÞ
ks IJJÞ
where N Jða;AÞ defines a J−dimensional Normal distribution with mean vector a and vari-
ance-covariance matrix A. The unknown variance was assumed to be common across all cell
types, denoted by s
2ðmÞ
ks IJJ where I is the identity matrix. This variance-covariance structure
was chosen for identifiability reasons given sample sizes available.
A Bayesian approach to model selection was adopted, which allowed for probabilistic state-
ments to be made about the relative fit of each candidate model. Under this approach, the pos-
terior probability of each model conditional on the observed data was calculated for all
candidate models. The posterior probability of model m compared to other candidates m0 was
Table 1. Description of cell-specific models based on cell lineage from Fig 1. Each candidate model cor-
responds to a partition of cell types into non-overlapping groups. Cell types within each set of parentheses, {},
belong to the same partition and were assumed to have the same level of methylation. For each cell-specific
model excluding ‘All’, the partition annotated by an asterisk (*) denotes the reference partition.
Candidate Model Differentially methylated
cell type(s)
Partition
Lymphocyte-I All Lymphocytes {CD19+},{CD4+},{CD8+},{CD56+},{CD14+,CD16+}*
Lymphocyte-II Lymphocytes excl. CD19+ B cells {CD4+},{CD8+},{CD56+},{CD19+,CD14+,CD16+}*
Myeloid All Myeloids {CD14+},{CD16+},{CD19+,CD4+,CD8+,CD56+}*
Pan T T cells {CD4+},{CD8+},{CD19+,CD56+,CD14+,CD16+}*
CD19+ B CD19+ B cells {CD19+},{CD4+,CD8+,CD56+,CD14+,CD16+}*
CD4+ T CD4+ T cells {CD4+},{CD19+,CD8+,CD56+,CD14+,CD16+}*
CD8+ T CD8+ T cells {CD8+},{CD19+,CD4+,CD56+,CD14+,CD16+}*
CD56+ NK CD56+ Natural Killers {CD56+},{CD19+,CD4+,CD8+,CD14+,CD16+}*
CD14+ Mono CD14+ Monocytes {CD14+},{CD19+,CD4+,CD8+,CD56+,CD16+}*
CD16+ Neu CD16+ Neutrophils {CD16+},{CD19+,CD4+,CD8+,CD56+,CD14+}*
All All available cell types {CD19+},{CD4+},{CD8+},{CD56+},{CD14+},{CD16+}
Null None {CD19+,CD4+,CD8+,CD56+,CD14+,CD16+}
https://doi.org/10.1371/journal.pone.0182455.t001
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calculated as,
Pr Model mjyksð Þ ¼
pðyksjModel mÞPrðModel mÞP
m0 pðyksjModel m0ÞPrðModel m0Þ
ð1Þ
where the sum of probabilities over all candidate models was equal to 1. The term p(yks|Model
m) was obtained by integrating over all unknown parameters from the likelihood and prior
distributions. Prior probabilities of each model, Pr(Model m), were assumed to be equal to
reflect a lack of model preference a priori.
Prior distributions for remaining parameters were selected such that Eq 1 could be derived
analytically. A g-prior distribution [19] was adopted for each μðmÞks ,
μðmÞks jgs; s
2
ks  N PðmÞ b0; gs
s
2ðmÞ
ks
ns
ðXTmXmÞ
  1
 !
:
The g-prior is a popular choice in linear model selection settings, as it allows the experi-
menter to introduce information on the scale of Xm. Expected methylation levels were cen-
tered around the overall methylation level, b0, with variance proportional the standard error of
each partition. The scaling factor gs> 0 is interpreted as a relative weighting of the prior versus
the observed data. Here, gs was assumed common over all CpG probes and estimated by maxi-
mising the marginal likelihood averaged over candidate models. In this paper, b0 was set to the
global methylation mean, averaged over CpGs and cell types. A conjugate prior distribution
for s
2ðmÞ
ks of form pðs
2ðmÞ
ks Þ / 1=s
2ðmÞ
ks completed model specification [19].
The expectation-maximisation (EM) algorithm was used to obtain a global Empirical Bayes
estimate for gs [20]. This computational approach provided significant computational benefits
over sampling-based approaches, namely Markov chain Monte Carlo (MCMC), and was pos-
sible given closed-form solutions for p(yks|Model m) conditional on gs. In addition, the desired
posterior model probabilities from Eq 1 were available upon convergence of the EM algorithm.
The proposed methodology was implemented in R, with code available as Supporting Infor-
mation (S1 File).
Making the most of the Bayesian approach for model based inference
The accommodation of model and parameter uncertainty under the Bayesian approach
formed the basis of subsequent inference, namely the identification of cell-specific CpGs, the
estimation of differential methylation by cell type and the assessment of sex-specific differ-
ences by cell type. Brief details of each inference are provided in this Section.
CpG marker identification. CpG probes or ‘markers’ associated with each cell-specific
pattern were identified by comparing posterior model probabilities at each CpG probe. For
each candidate model and sex, markers were identified by reviewing the set of K model proba-
bilities: Pr(Model m|y1s), . . ., Pr(Model m|yKs). A 5% Bayes’ False Discovery Rate (FDR) [21]
was applied to each set of probabilities to control the expected number of false discoveries.
Common CpG markers were defined as CpGs that were identified in both female and male
samples, for the same candidate model. The compilation of common marker panels allowed
for the assessment of sex-specific differences by cell type, within each candidate model.
Estimation of differential methylation. Posterior inference about each marker panel
focused on the estimation of differential methylation by cell type relative to its corresponding
reference partition (Table 1). Under model m, the posterior distribution of differential
Accounting for cell lineage and sex effects in the identification of cell-specific DNA methylation
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methylation for cell-specific partition p and sex s is,
m
ðmÞ
kps   m
ðmÞ
k1s  N m^
ðmÞ
ksp   m^
ðmÞ
ks1 ;
g^ s
1þ g^ s
s^
2ðmÞ
ks
ns
1
cðmÞp
þ
1
cðmÞ1
 ! !
ð2Þ
where cp is the number of cell types in partition p and ðμ^
ðmÞ
ks ; s^
2ðmÞ
ks Þ are posterior estimates of
each mean and residual variance, respectively, for which direct estimates were available. For
CpGs identified under each marker panel, Eq 2 was summarised in terms of a posterior mean
and 95% credible interval (CI). The posterior probabilities of differential methylation being
within selected ranges (<0.10, 0.10-0.20,0.20-0.30,0.30,0.40,0.40-0.50,>0.5), were also
calculated.
The posterior distribution in Eq 2 was also used to validate selected CpG markers. Valida-
tion of common CpG markers was limited to CD19+ B, CD4+ T, CD8+ T and Pan T models, in
light of validation samples available. Using all validation samples for each sex, the average β
−value for each cell type and CpG was computed. The difference between each average β
−value and reference partition was then compared with the corresponding 95% CI from Eq 2
for the appropriate candidate model. Concordance rates with respect to the predicted direction
of methylation (hypomethylated, hypermethylated) for validation samples were also calculated.
This joint approach was motivated by the limitation that validation based on coverage of 95%
CIs relied on a posterior estimate of s
2ðmÞ
ks . When this estimate is small and/or underestimated,
proportions of validated markers based on CI coverage only were likely to be low, even if dif-
ferences in methylation between training and validation samples were small. Finally, it is
noted that not all cell types observed in the training data were available in the validation sam-
ples. Given the properties of the multivariate Normal distribution, this discrepancy was
addressed by using the appropriate marginal distributions for the available cell types.
Evaluation of sex effects. A similar expression to Eq 2 was derived to evaluate sex-specific
methylation differences within common CpG marker panels. In this case, focus was on the
comparison of female and male methylation estimates for differentially methylated cell types,
as defined by the corresponding candidate model. The posterior distribution of this difference
across model partitions was Multivariate Normal,
μðmÞk1   μ
ðmÞ
k2  N PðmÞ ðμ^
ðmÞ
k1   μ^
ðmÞ
k2 ; s^
2ðmÞ
k1 Sm1 þ s^
2ðmÞ
k2 Sm2Þ ð3Þ
where μ^ðmÞks ¼
g^ s
1þg^ s
ðXTmXmÞ
  1XTmyks for s = 1,2. To assess evidence for sex effects, the posterior
probability that the difference in methylation between sexes using Eq 3 was at least 0.10 was
calculated for each cell-specific partition. This calculation again relied on estimates of the
residual variance, s^
2ðmÞ
ks for each sex which were set to their posterior mean estimate. A sex-spe-
cific difference for a given partition was declared if the posterior probability of a difference
greater than 0.10 exceeded 0.95.
CpG markers to genes: Assessment of SNP effects, genomic features
and pathway enrichment
To provide additional evidence to support our method of marker identification, a pathways
enrichment analysis was performed to explore the underlying biology of gene sets derived
from common CpG marker panels. Common CpG markers were mapped to genes using Illu-
mina Human Methylation 450K annotation data available from Bioconductor [22]. SNP infor-
mation was also collated to infer the percentage of SNP associated markers with associations
limited to SNPs located directly on the CpG loci. Using KEGG functional analysis in
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WebGestalt [23], a hypergeometric test was applied to each marker panel. A 5% FDR [24] was
applied to resulting p-values to identify significant pathway enrichment for derived gene lists.
Results
Cell lineage impacts the identification of differentially methylated CpGs
Across all cell-specific models, 83,449 and 97,747 CpG markers were identified for females and
males, respectively (Table 2). Among female samples, 42,834 markers (51.3%) were associated
with differential methylation in multiple cell types, which included a three-fold increase in Pan
T markers compared with males. A larger proportion of multi- cell-specific markers among
males was observed (64.8%), due to larger numbers identified under Lymphocyte-II and Mye-
loid models. Among single cell-specific models, CD19+B was the most frequently observed
marker type for both sexes, with 25,611 in females and 18,271 in males.
A total of 42,452 CpGs were associated with the same cell-specific methylation pattern for
both sexes, corresponding to 9.5% of the observed methylome. Within this subset, 23,551
(55.5%) were defined by differential methylation in more than one cell type. Over all candidate
models, smaller frequencies of common markers were associated with T cell-specific markers
(CD4+, CD8+, Pan T).
Differential methylation is affected by cell lineage among common CpG
markers
Common CpG markers associated with differential methylation in Myeloid cell types (CD14+
Mono, CD16+ Neu) were consistently hypomethylated across all relevant marker panels
(Table 3). Among Lymphocytes, CD8+T markers were the least likely to be hypomethylated
(35.99%). Smaller proportions of hypomethylation among Lymphocyte-I and II panels were
indicative of greater levels of methylation among Lymphocyte versus Myeloid cell subtypes.
The impact of cell lineage on differential methylation was greatest among marker panels
related to Lymphocytes (Fig 2). Lower levels of differential methylation (<0.10) were concen-
trated within single cell dependent markers (CD19+B, CD4+T, CD8+T, CD56+NK). In con-
trast, the comparison of distributions indicated a wider range of posterior estimates observed
for Pan T, Lymphocyte-I and Lymphocyte-II panels. The comparison of distributions associ-
ated with CD14+ Monocytes showed little evidence of being affected by cell lineage.
Table 2. Number of CpG markers identified by candidate model for females versus males, based on a 5% Bayes False Discovery Rate (FDR). For
each model, the number of common markers identified in both sexes is also listed. The number of CpGs identified for a single sex only are given in brackets
for each candidate model.
Candidate model Female Male Common
All 3873 (1699) 3553 (1379) 2174
Myeloid 12541 (3637) 29534 (20630) 8904
Lymphocyte-I 15596 (7369) 14105 (5878) 8227
Lymphocyte-II 4241 (1032) 14015 (10806) 3209
Pan T 6583 (5546) 2126 (1089) 1037
CD19+ B 25611 (11987) 18271 (4647) 13624
CD4+ T 1277 (821) 2050 (1594) 456
CD8+ T 2299 (1985) 2742 (2428) 314
CD56+ NK 4893 (3302) 4346 (2755) 1591
CD14+ Mono 1383 (627) 1681 (925) 756
CD16+ Neu 5152 (2992) 5324 (3164) 2160
https://doi.org/10.1371/journal.pone.0182455.t002
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The distribution of differential methylation by sex among common Pan T markers revealed
considerable variation for both hypermethylated and hypomethylated states compared to
CD4+T and CD8+ T panels (Fig 3). Differential methylation levels among Pan T markers
tended to be greater for CD4+ T cells; 25 markers in this subset showed strong evidence of dif-
ferential methylation greater than 0.5 for both sexes (S1 Fig).
Validation of common CpG markers for B- and T- lymphocytes
The validation of common markers with respect to mean differences was generally higher in
males than females, across immune cell subtypes (Table 4). Whilst validation based on cover-
age of credible intervals was low, differences between training and validation estimates were
relatively small across all markers tested (Fig 4); for CD4+T markers, approximately 80% of
absolute differences were less than 10% (S2 Fig). Furthermore, comparisons with respect to
inferred methylation state showed very high concordance rates for all marker panels and these
findings were consistent for both sexes.
Genomic feature distributions and enrichment analysis
The effects of cell lineage were evident in the comparison of genomic features, with higher pro-
portions of markers residing in Transcription Start Sites (TSS) for Lymphocyte cell subtypes
compared with Myeloids (Table 5). Common markers were concentrated in the gene body
and intergenic regions, with 54.73% of CD56+NK markers located in the gene body. Among
Lymphocyte cell subtypes, TSS proportions were highest for T cells, with 18.28% and 16.48%
for CD4+T and CD8+T cells, respectively.
Moderate proportions of markers were directly associated with SNPs and these levels were
maintained between sex-specific and common marker panels, averaging 30.7% in common
markers (S1 Table). Higher SNP proportions were observed in marker panels related to the
lineage of Myeloid cells, except for CD56+ NK markers of which 36.02% were SNP associated.
For CpG probes not assigned to any common marker panel, a similar degree of SNP associa-
tion was observed (26.61%).
Significant pathways enrichment for common markers were associated with immune cell
subtypes (Table 6) all including biologically relevant pathways.
Table 3. Percentage of hypomethylation among common markers by cell type and sex. Results are summarised for single cell-specific (CD19+B,
CD4+T,CD8+T,CD56+NK,CD14+Mono,CD16+Neu) and multi- cell-specific (Myeloid, Pan T, Lymphocyte-I, Lymphocyte-II) marker panels.
Sex Single cell-specific markers
CD19+B CD4+T CD8+T CD56+NK CD14+Mono CD16+Neu
Female 58.24 65.57 35.99 90.19 94.71 96.39
Male 58.24 65.57 35.99 90.19 94.71 96.39
Multi- cell-specific markers
Myeloid Female – – – – 93.53 93.41
Male – – – – 93.53 93.41
Pan T Female – 43.30 43.30 – – –
Male – 43.30 43.30 – – –
Lymphocyte-I Female 29.52 26.70 27.26 29.11 – –
Male 29.52 26.70 27.46 28.86 – –
Lymphocyte-II Female – 44.13 45.56 45.72 – –
Male – 44.13 45.65 45.81 – –
https://doi.org/10.1371/journal.pone.0182455.t003
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Assessment of common marker profiles shows sex effects in CD56+NK,
CD16+Neutrophils
The majority of common CpG markers did not exhibit sex-specific differences in methylation
profile (Table 7). Differences within CD56+NK and Lymphocyte-I/II panels indicated 12.32,
14.15 and 20.64% of respective markers exhibited sex effects, with the majority corresponding
Fig 2. Distribution of posterior mean estimates of differential methylation for each purified cell type across
corresponding marker panels. Posterior estimates are summarised for females (first column) and males (second column)
across common CpG markers.
https://doi.org/10.1371/journal.pone.0182455.g002
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to autosomal CpGs. No sex-specific differences were identified among common CD8+ T
markers.
Sex-specific differences identified among single cell-specific markers were uniquely
mapped to 215 genes (S2 Table). The majority of identified cases were concentrated in the
Fig 3. Posterior probability heatmaps for varying levels of differential methylation for common
CD4+T, CD8+T and Pan T markers. For each cell type, CpG markers (rows) are ordered the same for males
and females, to enable sex-specific comparisons. Markers are further classified by methylation state
(Hypomethylated, Hypermethylated), based on their posterior mean estimate of differential methylation. First
row (L-R): CD4+T, CD8+T; Second row: Pan T.
https://doi.org/10.1371/journal.pone.0182455.g003
Table 4. Percentage of validated, common CpG markers based on the coverage of 95% credible inter-
vals inferred from the training data, by sex and marker type. The outcome of interest for validation was
the estimated difference in methylation. For Pan T markers, results are summarised by individual cell type and
jointly, the latter corresponding to both CD4+T and CD8+T differences being validated for the same marker.
Differential methylation Methylation state
Marker panel Female Male Female Male
CD19+B 36.9 25.8 99.9 99.7
CD4+T 37.7 53.9 97.6 100
CD8+T 38.1 63.4 98.6 99.7
PanT 21.4 31.6 99.7 99.5
Pan T: CD4+T only 46.7 54.5 100 100
Pan T: CD8+T only 42.7 41.1 99.7 99.5
https://doi.org/10.1371/journal.pone.0182455.t004
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Fig 4. Validation of common marker panels for immune cell subtypes, based on the comparison of
mean differences for each cell type relative to its corresponding reference partition. For each marker
type, posterior mean differences inferred from the training data (x-axis) are compared with the average mean
difference calculated from the validation data (y-axis). Estimates of each posterior mean difference are
accompanied by a respective 95% CI. Validated markers based on the coverage of each 95%CI are indicated
in black. First row (L-R): CD19+, CD4+ T; Second row (L-R): CD8+ T, Pan T. CI: Credible interval.
https://doi.org/10.1371/journal.pone.0182455.g004
Table 5. Distribution of genomic features among common CpG markers by cell-specific methylation pattern.
Marker panel 1stExon 3’UTR 5’UTR Body Intergenic TSS1500 TSS200
Myeloid 2.88 5.90 11.17 46.85 15.41 13.65 4.14
Lymphocyte-I 4.10 4.20 14.26 40.84 13.26 17.05 6.28
Lymphocyte-II 3.58 4.31 14.48 40.68 12.92 18.15 5.88
anT 4.32 2.19 14.29 40.75 13.26 17.98 7.20
CD19+B 7.07 4.32 13.55 38.71 13.81 14.20 8.35
CD4+T 3.79 3.52 15.14 41.64 12.40 18.28 5.22
CD8+T 6.67 2.78 12.59 38.52 13.15 16.48 9.81
CD56+NK 2.21 5.07 12.17 54.73 12.43 9.80 3.59
CD14+Mono 1.72 4.38 10.47 47.30 20.60 11.33 4.21
CD16+Neu 1.72 8.12 10.63 53.68 12.21 10.89 2.75
https://doi.org/10.1371/journal.pone.0182455.t005
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CD56+ NK common marker panel. Four CD4+ T markers were associated with greater meth-
ylation observed in females and were mapped to a single gene, CD40LG, located on the X chro-
mosome. Sex-specific differences and annotation information for all common markers
identified is provided in the Supplementary Material (S2 File).
Sex effects in CD56+ NK methylation were prominent in Lymphocyte-I and Lymphocyte-II
common marker panels, in addition to the CD56+ NK panel (Fig 5). Within the Lymphocyte-I
panel, 1698 common CpG markers were identified as sex-specific, of which 1627 showed dif-
ferences in CD56+ NK methylation only. Similarly, 442 common Lymphocyte-II markers
Table 6. Summary of biologically relevant pathways identified in enrichment analysis of common marker panels. All pathways were identified based
on a Benjamini-Hochberg (BH) adjusted p-value < 0.05.
Marker panel Pathway p-value
CD14+Monocytes Fc gamma R-mediated phagocytosis 0.01
Cytokine-cytokine receptor interaction 0.04
CD19+B B cell receptor signaling pathway 2.84×10−13
T cell receptor signaling pathway 3.07×10−11
Fc epsilon RI signaling pathway 4.58×10−9
CD4+T T cell receptor signaling 2.73×10−7
Antigen processing and presentation 0.0002
Cytokine-cytokine receptor interaction 0.0007
CD8+T Antigen processing and presentation 0.02
CD56+NK Natural killer cell mediated cytotoxicity 6.35×10−5
Chemokine signaling pathway 4.85×10−5
T cell receptor signaling pathway 0.0003
CD16+Neu Endocytosis 1.07×10−8
Chemokine signaling pathway 0.0002
Fc gamma R-mediated phagocytosis 0.0003
Phagosome 0.04
Pan T Chemokine signaling pathway 3.33 ×10−5
T cell receptor signaling pathway 0.0005
B cell receptor signaling pathway 0.004
Natural killer cell mediated cytotoxicity 0.005
https://doi.org/10.1371/journal.pone.0182455.t006
Table 7. Summary of sex-specific differences by common CpG marker panel. A difference between male and female methylation estimates0.10 was
the outcome of interest. A marker was declared sex-specific if the posterior probability for this outcome exceeded 0.95, for one or more model-based parti-
tions. For each marker panel, total numbers of sex-specific markers and autosomal sex-specific markers are given.
Non sex-specific Sex-specific differences
Marker panel (%) Total Total Autosomal
Myeloid 91.69 740 685
Lymphocyte-I 79.36 1698 1635
Lymphocyte-II 85.85 454 444
Pan T 99.42 6 2
CD19+ B 99.75 34 11
CD4+ T 98.90 5 1
CD8+ T 100 0 0
CD56+ NK 87.68 196 194
CD14+ Mono 99.07 7 4
CD16+ Neu 96.67 72 66
https://doi.org/10.1371/journal.pone.0182455.t007
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showed differences in CD56+ NK methylation between sexes. The tendency for CD56+ NK
methylation to be higher in males was common across all three panels.
684 common Myeloid markers were associated with differences in CD14+ Monocytes or
CD16+ Neutrophils only. Differences with respect to CD14+ Monocytes tended to be higher in
females, compared with higher male methylation in CD16+ Neutrophils (Fig 6).
Discussion
This paper has proposed new statistical methodology for the discovery of cell-specific methyla-
tion profiles in whole blood, applying principles of Bayesian model selection. The characterisa-
tion of CpGs by differential methylation in one or more cell types builds significantly upon
existing work that has been restricted to univariate analyses of differential methlyation by cell
type. Sex-specific differences in both the prevalence of cell-specific profiles and methylation
signal for select cell types were also demonstrated. For immune cell subtypes, validation of
common markers using external cell-sorted samples produced favourable results. Enrichment
analyses of common marker panels provided additional support for the proposed methodol-
ogy, where it was demonstrated that the detection of cell-specific methylation at the individual
CpG level was also biologically meaningful.
Fig 5. Posterior summaries of sex-specific differences in selected common marker panels defined by differences in CD56+
NK methylation only. Each difference is summarised by the posterior mean estimate and corresponding 95% CI. The shaded region
corresponds to a difference of ±0.1. L-R: CD56+ NK, Lymphocyte-I, Lymphocyte-II.
https://doi.org/10.1371/journal.pone.0182455.g005
Fig 6. Posterior summaries of sex-specific differences in common Myeloid markers defined by
differences in CD14+Monocytes (Left) or CD16+ Neutrophils (Right) only. The difference at each marker
is summarised by the posterior mean and corresponding 95% CI. The shaded region corresponds to a
methylation difference of ± 0.10.
https://doi.org/10.1371/journal.pone.0182455.g006
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The adoption of a Bayesian approach was motivated by the benefits it offered over tradi-
tional approaches to model selection. The calculation of posterior model probabilities pro-
vided an informative measure of model evidence that accounted for selection uncertainty
between multiple competing hypotheses [25]. The availability of these probabilities therefore
enabled multiple candidate models to be compared simultaneously. Resulting probabilities
were also used directly to identify CpG markers associated with each cell-specific pattern,
whilst controlling for a defined false discovery rate. Whilst equal prior weights were assumed
for all candidate models, other specifications are possible [26]. Future research in this area
should consider alternative prior specifications and their impact on marker identification. For
example, spatial structure among neighbouring CpGs could be incorporated, shifting the
emphasis of identification to cell-specific differentially methylated regions (DMRs), offering
an alternative to current statistical approaches [27].
The incorporation of knowledge about hematopoietic lineage into model specification rep-
resents a semi-supervised approach that reflects relevant cell biology. Consistent with other
model selection strategies, our approach assumes that the defined set of candidate models is
exhaustive and true patterns beyond this set are not of primary interest. In the event that the
true methylation pattern does not align with any of the candidate models specified, two out-
comes are likely. In the first instance, corresponding probes are assigned to the saturated
model and may be examined further as part of a larger marker panel. Alternatively, the vector
of model probabilities for each CpG may be diffuse over multiple possibilities and therefore
not be identified for any cell-specific pattern under the chosen criteria. The feasibility of unsu-
pervised approaches to model selection, where the full list of methylation patterns is deter-
mined by the observed data is appealing, but their routine application in high dimensional
settings is prohibitive. Furthermore, there is potential for patterns identified to be an artefact
of random noise present in cell sorted samples as opposed to true biological signal. Integrated
methods of model selection represent an avenue for future work, where new cell-specific pat-
terns are proposed based on the combination of cell lineage and their prevalence in the
observed methylome.
It is well documented that there are sex-specific differences in the proportions of circulating
white blood cells [28, 29]. The application of the proposed methodology to female and male
samples has highlighted the importance of accounting for sex effects in DNA methylation anal-
yses. Greater numbers of CD19+B and T cell-specific markers in females are consistent with
previous findings and are possibly indicative of higher levels of cell activation [30]. The associ-
ation between sex-specific differences in select CD4+T markers and the CD40LG gene have
also been identified previously. Previous studies have pointed to allele specific methylation for
this gene [31, 32] where CD4+T hypomethylation is observed in healthy males compared with
healthy women who carry one methylated and one hypomethylated allele. One of our major
findings was large differences of methylation between males and females in markers defined as
CD56+NK specific. This is interesting when considered alongside the observation that males
show an increase in circulatory NK cells compared to females [30], which adds further support
for the accuracy of the approach. Additionally there is some evidence of sex-specific methyla-
tion differences in CD56+ NK, as well as CD8+ T cells [33]. Under the proposed approach, we
have provided a potential solution to accurately account for potential bias introduced by sex
effects at the marker level.
The presence of cell-specific CpG markers highlights the need to account for cellular com-
position prior to conducting Epigenome Wide Association Studies (EWAS), in whole blood.
Methods for this purpose have been developed [34, 35] based on the assembly of methylation
‘signatures’ from cell-sorted data which are then projected onto heterogeneous samples to pre-
dict cell type proportions. The inclusion of other marker panels identified in our study may
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lead to further improvement in cell mixture estimation, in particular for immune cell subtypes
that may be present in low proportions. Furthermore, the performance of these algorithms
rely on consistent cell-type effects across cohorts [36]. Given the sex-specific methylation dif-
ferences we have identified in this study, failure to account for sex effects may also impact
upon the quality of cell mixture estimation and should therefore be given due consideration.
It is common practice in array-based methylation studies to exclude CpG sites which con-
tain SNPs both within the probe and on the CpG site. While this is a valid approach to filtering
before analysis, it will often lead to dramatic reduction of overall data. As a result, it is likely
that sites of potential interest may be lost before any association can be made. By mapping
hg38 annotated SNPs to all 450K CpG loci, we were able to ascertain the overall proportion of
cell marker sites which have a SNP present; on average, across the common set of markers, this
was approximately 30.7% of markers. In light of these results, we suggest that deconvolution
studies and methods should account for SNP events at cell marker sites, noting the proportion
that are present. For the filtering stage, we recommend that the overall rarity of the SNP vari-
ant be taken into account, for example, retaining CpGs which also have a rare (MAF < 0.01)
variant mapping. This approach is likely to be beneficial to the overall study design and
outcome.
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ers by candidate model. The category ‘Unassigned’ refers to all CpG probes that were not
assigned to any marker panel, based on a 5% Bayes’ FDR.
(PDF)
S2 Table. Distribution of sex-specific common markers over chromosomes, for single cell-
dependent makers only. A sex-specific marker was declared if the posterior probability of a
methylation difference 0.10 was greater than 0.95 for at least one cell type.
(PDF)
S1 Fig. Distribution of observed methylation β−values by cell type and sex for selected
common Pan T markers. Markers were identified as having high levels of differential methyl-
ation (>0.5) in CD4+ T cells. Markers were identified if the corresponding posterior probabil-
ity of differential methylation >0.5 exceeded 0.95.
(TIFF)
S2 Fig. Validation analysis: Empirical cumulative distribution function (CDF) of the abso-
lute difference between posterior and validation estimates by validation status. Validation
status was defined by the coverage of each 95% CI, estimated from the training data. First row
(L-R): CD19+B, CD4+T; Second row (L-R): CD8+T, Pan T.
(TIFF)
S1 File. R code for Bayesian model selection algorithm. Core R functions required to prepare
data and compute posterior model probabilities via the EM algorithm, across all listed candi-
date models.
(ZIP)
S2 File. List of common CpG markers associated with a sex-specific difference of0.10.
Illumina Human Methylation 450K annotation data are also included for each CpG marker.
(XLSX)
Accounting for cell lineage and sex effects in the identification of cell-specific DNA methylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0182455 September 28, 2017 15 / 18
Acknowledgments
We thank Peter Donnelly for his helpful feedback on the methodology developed in this paper.
MB and NW were supported by a collaborative development grant from QUT. NW was fur-
ther supported by the Australian Research Council (ARC) working under a Laureate Fellow-
ship held by KM. DK is supported by an Australian Government Research Training Program
(RTP) Scholarship, and an ARC Centre of Excellence for Mathematical and Statistical Fron-
tiers (ACEMS) top-up scholarship. AF and RL are partially supported by Multiple Sclerosis
Research Australia funding for bioinformatics.
Author Contributions
Conceptualization: Nicole White, Miles Benton, Daniel Kennedy, Rodney Lea.
Data curation: Miles Benton, Andrew Fox.
Formal analysis: Nicole White, Miles Benton.
Funding acquisition: Lyn Griffiths, Kerrie Mengersen.
Investigation: Andrew Fox.
Methodology: Nicole White.
Supervision: Lyn Griffiths, Rodney Lea, Kerrie Mengersen.
Writing – original draft: Nicole White, Miles Benton.
Writing – review & editing: Nicole White, Miles Benton, Daniel Kennedy, Andrew Fox, Lyn
Griffiths, Rodney Lea, Kerrie Mengersen.
References
1. Muers M. Gene expression: Disentangling DNA methylation. Nat Rev Genet. 2013; 14(8):519–519.
https://doi.org/10.1038/nrg3535 PMID: 23797851
2. Meissner A, Mikkelsen TS, Gu H, Wernig M, Hanna J, Sivachenko A, et al. Genome-scale DNA methyl-
ation maps of pluripotent and differentiated cells. Nature. 2008; 454(7205) 766–770. https://doi.org/10.
1038/nature07107 PMID: 18600261
3. Hashimshony T, Zhang J, Keshet I, Bustin M, Cedar H. The role of DNA methylation in setting up chro-
matin structure during development. Nature Genetics. 2003; 34(2):187–192. https://doi.org/10.1038/
ng1158 PMID: 12740577
4. Dedeurwaerder S, Defrance M, Bizet M, Calonne E, Bontempi G, Fuks F. A comprehensive overview of
Infinium HumanMethylation450 data processing. Briefings in bioinformatics. 2014; 15(6): 929–941.
https://doi.org/10.1093/bib/bbt054 PMID: 23990268
5. Dedeurwaerder S, Defrance M, Calonne E, Denis H, Sotiriou C, Fuks F. Evaluation of the Infinium Meth-
ylation 450K technology. Epigenomics. 2011; 3(6): 771–784. https://doi.org/10.2217/epi.11.105 PMID:
22126295
6. Sandoval J, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, et al. Validation of a DNA
methylation microarray for 450,000 CpG sites in the human genome. Epigenetics. 2011; 6(6):692–702.
https://doi.org/10.4161/epi.6.6.16196 PMID: 21593595
7. Rakyan VK, Beyan H, Down TA, Hawa MI, Maslau S, Aden D, et al. Identification of type 1 diabetes—
associated DNA methylation variable positions that precede disease diagnosis. PLoS Genetics 2011; 7
(9):e1002300. https://doi.org/10.1371/journal.pgen.1002300 PMID: 21980303
8. Franco R, Schoneveld O, Georgakilas AG, Panayiotidis MI. Oxidative stress DNA methylation and car-
cinogenesis. Cancer Letters. 2008; 266(1):6–11. https://doi.org/10.1016/j.canlet.2008.02.026 PMID:
18372104
9. Houseman EA, Kim S, Kelsey KT, Wiencke JK. DNA methylation in whole blood: uses and challenges.
Current Environmental Health Reports. 2015; 2(2):145–154. https://doi.org/10.1007/s40572-015-0050-
3 PMID: 26231364
Accounting for cell lineage and sex effects in the identification of cell-specific DNA methylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0182455 September 28, 2017 16 / 18
10. Adalsteinsson BT, Gudnason H, Aspelund T, Harris TB, Launer LJ, Eiriksdottir G, et al. Heterogeneity
in white blood cells has potential to confound DNA methylation measurements. PloS One. 2012; 7(10):
e46705. https://doi.org/10.1371/journal.pone.0046705 PMID: 23071618
11. Bocker MT, Hellwig I, Breiling A, Eckstein V, Ho AD, Lyko F. Genome-wide promoter DNA methylation
dynamics of human hematopoietic progenitor cells during differentiation and aging. Blood. 2011; 117
(19):e182–e189. https://doi.org/10.1182/blood-2011-01-331926 PMID: 21427290
12. Glossop JR, Nixon NB, Emes RD, Haworth KE, Packham JC, Dawes PT, et al. Epigenome-wide profil-
ing identifies significant differences in DNA methylation between matched-pairs of T- and B-lympho-
cytes from healthy individuals. Epigenetics. 2013; 8(11):1188–1197. https://doi.org/10.4161/epi.26265
PMID: 24005183
13. Reinius LE, Acevedo N, Joerink M, Pershagen G, Dahle´n SE, Greco D, et al. Differential DNA methyla-
tion in purified human blood cells: implications for cell lineage and studies on disease susceptibility.
PloS One. 2012; 7(7):e41361. https://doi.org/10.1371/journal.pone.0041361 PMID: 22848472
14. El-Maarri O, Becker T, Junen J, Manzoor SS, Diaz-Lacava A, Schwaab R, et al. Gender specific differ-
ences in levels of DNA methylation at selected loci from human total blood: a tendency toward higher
methylation levels in males. Human Genetics. 2007; 122(5):505–514. https://doi.org/10.1007/s00439-
007-0430-3 PMID: 17851693
15. Liu J, Morgan M, Hutchison K, Calhoun VD. A study of the influence of sex on genome wide methyla-
tion. PloS One. 2010; 5(4):e10028. https://doi.org/10.1371/journal.pone.0010028 PMID: 20386599
16. Eckhardt F, Lewin J, Cortese R, Rakyan V, Attwood J, Burger M, et al. DNA methylation profiling of
human chromosomes 6, 20 and 22. Nature Genetics. 2006; 38(12):1378–1385. https://doi.org/10.1038/
ng1909 PMID: 17072317
17. McCarthy NS, Melton PE, Cadby G, Yazar S, Franchina M, Moses EK, et al. Meta-analysis of human
methylation data for evidence of sex-specific autosomal patterns. BMC Genomics. 2014; 15:981.
https://doi.org/10.1186/1471-2164-15-981 PMID: 25406947
18. Mamrut S, Avidan N, Staun-Ram E, Ginzburg E, Truffault F, Berrih-Aknin S, et al. Integrative analysis of
methylome and transcriptome in human blood identifies extensive sex-and immune cell-specific differ-
entially methylated regions. Epigenetics. 2015; 10(10):943–957. https://doi.org/10.1080/15592294.
2015.1084462 PMID: 26291385
19. Zellner A. On assessing prior distributions and Bayesian regression analysis with g-prior distributions.
In: Goel PK, Zellner A, editors. Bayesian inference and decision techniques: Essays in Honor of Bruno
De Finetti. Amsterdam: North-Holland; 1986. pp. 233–243.
20. Liang F, Paulo R, Molina G, Clyde MA, Berger JO. Mixtures of g priors for Bayesian variable selection.
Journal of the American Statistical Association. 2012; 103(481):410–423. https://doi.org/10.1198/
016214507000001337
21. Newton MA, Noueiry A, Sarkar D, Ahlquist P. Detecting differential gene expression with a semipara-
metric hierarchical mixture method. Biostatistics. 2004; 5(2):155–176. https://doi.org/10.1093/
biostatistics/5.2.155 PMID: 15054023
22. Triche Jr T. IlluminaHumanMethylation450k.db: Illumina Human Methylation 450K annotation data. R
package version 2.0.9. 2014.
23. Wang J, Duncan D, Shi Z, Zhang B. WEB-based GEne SeT AnaLysis Toolkit (WebGestalt): Update
2013. Nucleic Acids Research. 2013; 41:W77–W83. https://doi.org/10.1093/nar/gkt439 PMID:
23703215
24. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to mul-
tiple testing. Journal of the Royal Statistical Society Series B (Methodological). 1995; 57(1):289–300.
25. Friel N, Wyse J. Estimating the evidence–a review. Statistica Neerlandica. 2012; 66(3):288–308.
https://doi.org/10.1111/j.1467-9574.2011.00515.x
26. Fernandez C, Ley E, Steel MF. Benchmark priors for Bayesian model averaging. Journal of Economet-
rics. 2001; 100(2):381–427. https://doi.org/10.1016/S0304-4076(00)00076-2
27. Chen DP, Lin YC, Fann CS. Methods for identifying differentially methylated regions for sequence- and
array-based data. Briefings in Functional Genomics. 2016; 15(6): 485–490. PMID: 27323952
28. Fish EN. The X-files in immunity: sex-based differences predispose immune responses. Nature
Reviews Immunology. 2008; 8(9):737–744. https://doi.org/10.1038/nri2394 PMID: 18728636
29. Klein SL, Flanagan KL. Sex differences in immune responses. Nature Reviews Immunology. 2016; 16
(10):626–638. https://doi.org/10.1038/nri.2016.90 PMID: 27546235
30. Abdullah M, Chai P, Chong M, Tohit E, Ramasamy R, Pei C, et al. Gender effect on in vitro lymphocyte
subset levels of healthy individuals. Cellular Immunology. 2012; 272(2):214–219. https://doi.org/10.
1016/j.cellimm.2011.10.009 PMID: 22078320
Accounting for cell lineage and sex effects in the identification of cell-specific DNA methylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0182455 September 28, 2017 17 / 18
31. Schmidl C, Klug M, Boeld TJ, Andreesen R, Hoffmann P, Edinger M, et al. Lineage-specific DNA meth-
ylation in T cells correlates with histone methylation and enhancer activity. Genome Research. 2009; 19
(7):1165–1174. https://doi.org/10.1101/gr.091470.109 PMID: 19494038
32. Jeffries M, Dozmorov M, Tang Y, Merrill JT, Wren JD, Sawalha AH. Genome-wide DNA methylation
patterns in CD4+ T cells from patients with systemic lupus erythematosus. Epigenetics. 2011; 6
(5):593–601. https://doi.org/10.4161/epi.6.5.15374 PMID: 21436623
33. Inoshita M, Numata S, Tajima A, Kinoshita M, Umehara H, Yamamori H, et al. Sex differences of leuko-
cytes DNA methylation adjusted for estimated cellular proportions. Biology of Sex Differences. 2015;
6:11. https://doi.org/10.1186/s13293-015-0029-7 PMID: 26113971
34. Houseman EA, Accomando WP, Koestler DC, Christensen BC, Marsit CJ, Nelson HH, et al. DNA meth-
ylation arrays as surrogate measures of cell mixture distribution. BMC Bioinformatics. 2012; 13:86.
https://doi.org/10.1186/1471-2105-13-86 PMID: 22568884
35. Koestler DC, Jones MJ, Usset J, Christensen BC, Butler RA, Kobor MS, et al. Improving cell mixture
deconvolution by identifying optimal DNA methylation libraries (IDOL). BMC Bioinformatics. 2016;
17:120. https://doi.org/10.1186/s12859-016-0943-7 PMID: 26956433
36. Yousefi P, Huen K, Quach H, Motwani G, Hubbard A, Eskenazi B, et al. Estimation of blood cellular het-
erogeneity in newborns and children for epigenome-wide association studies. Environmental and
Molecular Mutagenesis. 2015; 56(9):751–758. https://doi.org/10.1002/em.21966 PMID: 26332589
Accounting for cell lineage and sex effects in the identification of cell-specific DNA methylation
PLOS ONE | https://doi.org/10.1371/journal.pone.0182455 September 28, 2017 18 / 18
